GSK Sweetens Early-Stage Diabetes Pipeline With HGS’ Albugon
This article was originally published in The Pink Sheet Daily
Executive Summary
The preclinical peptide hormone will likely be developed for Type-2 diabetes. Human Genome Sciences believes potential advantage with Albugon is prolonged half-life.
You may also be interested in...
Human Genome Sciences CEO Is Former TAP President Thomas Watkins
Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.
Human Genome Sciences CEO Is Former TAP President Thomas Watkins
Watkins joins HGS after serving as head of TAP Pharmaceuticals for six years. HGS focused its CEO search on candidates with late-stage product development experience; the firm's lead candidate LymphoStat-B is in Phase II for RA and lupus.
Liraglutide Phase III Diabetes Program Delayed Until 2005
Novo Nordisk expects its glucagon-like peptide-1 analog liraglutide to enter Phase III trials in 2005